Home ›
Breast Cancer Trials ›
NCT07008976
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
This study adopted a randomized, open-label, positive drug-controlled, multi-center trial design. The primary endpoint was PFS evaluated by the Independent Review Committee (IRC). Eligible subjects were randomly assigned in a 1:1 ratio to receive either TQB2102 for injection or trastuzumab emtansine for injection.
Trial Details
NCT ID NCT07008976
Phase PHASE3
Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status RECRUITING
Cancer Type Breast Cancer
Interventions TQB2102 Injection Trastuzumab Emtansine for Injection
Locations (sample) Bengbu, Anhui, China|32.94083,117.36083 Hefei, Anhui, China|31.86389,117.28083 Hefei, Anhui, China|31.86389,117.28083 Beijing, Beijing Municipality, China|39.9075,116.39723 Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
The subjects voluntarily participated in this study, signed the informed consent form, and had good compliance; Age: 18 - 75 years old (at the time of signing the informed consent form); Eastern Cooperative Oncology Group (ECOG )score ≤ 1; Expected survival p… HER2-positive, unresectable, locally advanced or metastatic invasive breast cancer confirmed by histopathological or cytological examination; According to the 2018 version of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP )HumanEpidermalGrowthFactor…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →